

CERTIFIED NURSE PRACTITIONER

Accomplished and patient-focused professional with comprehensive experience providing excellent care to patients with acute and chronic common health problems. Experience in coordinating with treatment teams to formulate and execute individualized patient plans, aiming to maximize care, and supporting patients' lives. Adept at delivering individual counseling to patients and families to provide executive-level assistance. Possess strong expertise in conducting procedures and treatments, within the scope of training and experience, as ordered by the physician following established protocols. Instrumental in documenting outcomes in the patient records while ensuring high-performance standards. Demonstrates good judgment in selecting methods and techniques for obtaining the best suitable solutions to overcome and eliminate the root-cause of issues. Well-versed at supporting clinical functions to prepare the patient for examination, treatment, or procedures in compliance with regulatory protocols.

CAREER DEVELOPMENT

2005 to Present: Savannah Neurology Specialist, Savannah, GA

➔ Nurse Practitioner

Hold full accountability for managing overall care operations of neurological patients including diagnostics and treatment across the acute care setting. Collaborate with neurologists and other healthcare providers to deliver appropriate care for admitted patients, home/rehabilitation care facilities, and nursing homes. Provide counseling to patients and their families on health maintenance/promotion, disease prevention/management, and medication use.

- ❖ Attended community programs/health fairs and delivered impactful presentations, lectures, and screenings (i.e. stroke risk screenings, multiple sclerosis, etc.) at community venues and arenas.
- ❖ Played an integral role as a sub-investigator for in-office clinical research led by Meridian Research, LLC.

2003 to 2005: Savannah Neurology Specialist, Savannah, GA

➔ Nurse Practitioner | Research Coordinator

Oversaw care provided to neurological patients while coordinating with neurologists to complete acute interdisciplinary rehabilitative rounds. Conducted comprehensive health evaluations, diagnosis, and treatment for patients in line with regulatory protocols.

- ❖ Performed multiple clinical trials including WASID "Warfarin vs. Aspirin for Symptomatic Intracranial Disease"; NIH; ABOVE Multiple Sclerosis Trial; and The ProFess Clinical Trial.

EARLY CAREER

➔ **Director – Stroke Risk Reduction Program** | Research Coordinator, Neurological Institute Of Savannah, Savannah, GA

➔ **Staff Nurse – Emergency Room**, Memorial Health University Medical Center, Savannah, GA

➔ **Clinical Nurse**– Orthopedics/Neurology/Rehabilitation, Memorial Health University Medical Center, Savannah, GA

➔ **Nurse Clinician** – Orthopedics/Neurology/Rehabilitation, Memorial Health University Medical Center, Savannah, GA

➔ **Staff Nurse** – Neurology/Neurosurgery, Nursing Assistant – Labor & Delivery/Medical-Surgical Trauma Unit/Telemetry

EDUCATION & CERTIFICATIONS

Doctor of Philosophy in Nursing, PhD, May, The Catholic University of America, Washington, D.C, 2019
"Facilitators and Barriers of Self-Management in Adults with Multiple Sclerosis" Protocol No. 18-028

Post Masters of Science in Nursing | Family Nurse Practitioner, Georgia Southern University, Statesboro, GA

Masters of Science in Nursing | Adult Clinical Nurse Specialist, Armstrong Atlantic State University, Savannah, GA

Bachelor of Science in Nursing, Armstrong Atlantic State University, Savannah, GA

Board Certified Family Nurse Practitioner – American Nurses Credentialing Center (ANCC) | Certified Neuroscience Registered Nurse, CNRN – American Board of Neuroscience Nursing (ABNN) | Multiple Sclerosis Certified Nurse, MSCN – International Organization of Multiple Sclerosis Nurses (IOMSN) | Multiple Sclerosis Nurses International Certification Board (MSNICB) | Collaborative Institutional Training Initiative (CITI Program)



PROFESSIONAL AFFILIATIONS

- American Nurses' Association: 00503006
- American Association of Neuroscience Nurses: 00013572
- Sigma Theta Tau-International Honor Society of Nursing: 0189679
- Board Member, International Organization of Multiple Sclerosis Nurses: 2254
- Active Member, Consortium of Multiple Sclerosis Centers (CMSC),
- Board Member, Multiple Sclerosis Nurses International Certification Board, 2018-2020
- Executive Board Member, SMA Angels Charity, Inc.
- Representative – Georgia Board of Examiners for NCLEX-PN/State Board of Nursing
- Who's Who Among Students in American Universities and Colleges
- Savannah Exchange Club's President's Cup Recipient
- Shirley Hood-Bryant Memorial Health's Nursing Scholarship
- Presidential Honor - Armstrong Atlantic State University
- Outstanding Scholar Athlete of Armstrong Atlantic State University

RESEARCH HISTORY

- **Present Sub-Investigator – May 2018**, Adamas. “A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment.”
- **Present Protocol MNK14274069 Sub-Investigator – June 2018**, Mallinckrodt Pharmaceuticals. “A Multicenter, Randomized, Double Blind Placebo Controlled Parallel Group Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects with Relapsing-Remitting Multiple Sclerosis.”
- **Present Protocol COL MIG-302 Sub-Investigator – October 2016**, CoLucid Pharmaceuticals, Inc. “A Study of Three Doses of Lasmiditan (50 mg, 100 mg, and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study (SPARTAN).”
- **Present Protocol COL MIG-305 Sub-Investigator – October 2016**, CoLucid Pharmaceuticals, Inc. “An Open-Label, Long-Term Safety Study of Lasmiditan (100 mg and 200 mg) in the Acute Treatment of Migraine (GLADIATOR).”
- **Present Protocol E2007-G000-311 Sub-Investigator Eisai Inc. – October 2016**, “An open-label, multicenter study with an extension phase to evaluate the safety, tolerability, and exposure-efficacy relationship of perampanel oral suspension when administered as an adjunctive therapy in pediatric subjects (age 4 to less than 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures.”
- **Present Protocol SA-309JG EDSS Examining Investigator Chugai Pharmaceuticals – June 2016**, “A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).”
- **Present Protocol COMB157G2301 EDSS Examining Investigator Novartis – June 2016**, “A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of multiple sclerosis.”
- **Present Protocol MRZ60201_3072_1 Sub-Investigator Merz Pharmaceuticals– February 2016**, “Prospective, Multicenter, Randomized, Double-Blind, Parallel Group, Dose-Response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 – 17 Years) with Cerebral Palsy.”
- **Present Protocol ACRIN 7155 Sub-Investigator American College of Radiology – February 2016**, “Imaging dementia - evidence for amyloid scanning (IDEAS) study: A coverage with evidence development longitudinal cohort study.”
- **Current Protocol 109MS401 Sub-Investigator Biogen Idec MA, Inc. – December 2015**, “A Multi-Center, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM).”